Page last updated: 2024-10-28

guaifenesin and Neuromuscular Diseases

guaifenesin has been researched along with Neuromuscular Diseases in 6 studies

Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.

Neuromuscular Diseases: A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA.

Research Excerpts

Excerpt	Relevance	Reference
"Cough is a natural reflex that protects respiratory airways against infections or mucus retention."	1.40	[Therapeutic strategies to increase the effectiveness of cough]. ( Céspedes, J; Monge, G; Puppo, H; Torres-Castro, R; Vera, R; Vilaró, J, 2014)

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (16.67)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (66.67)	29.6817
2010's	1 (16.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hartmann-von Monakow, K	1
Torres-Castro, R	1
Monge, G	1
Vera, R	1
Puppo, H	1
Céspedes, J	1
Vilaró, J	1
Panitch, HB	2
Boitano, LJ	1
Haas, CF	1
Loik, PS	1
Gay, SE	1

Clinical Trials (2)

Trial Overview

Trial	Enrollment	Study Type	Start Date	Status
Comparison of a Hyperinflation Mode and Air Stacking on Neuromuscular Patients Under Volumetric Ventilation[NCT02847299]	20 participants (Actual)	Interventional	2016-09-30	Completed
A Chart Review Assessing the Effects of Nebulised Hypertonic Saline on Respiratory-related Complications in Children and Young People With Neuromuscular Disease and Cerebral Palsy[NCT03623698]	24 participants (Actual)	Observational	2018-06-15	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

%SpO2

Nocturnal oxygen saturation (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	percentage of SpO2 (Mean)
Before Treatment	96.55
After Treatment	96.53

AHI

Nocturnal Apnoea Hipopnea index: total number of apnea events plus hypopnea events divided by the total number of minutes of actual sleep time and then multiplied by 60. (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	Events per hour of sleep (Mean)
Before Treatment	8.53
After Treatment	1.38

Apnea Index (AI)

The number of apneas recorded during the study per hour of sleep (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	Events per hour of sleep (Mean)
Before Treatment	4.87
After Treatment	0.40

FEV1/FVC %Predicted Rate of Decline

Rate of decline per year of Tiffenau index (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	percentage of predicted (Median)
Before Treatment	97.37
After Treatment	98.89

FEV1% Predicted Rate of Decline

"Rate of decline of Forced Expiratory Volume in first second (FEV1) percentage of predicted.~Rate of decline is a measure of slope of FEV1 percentage predicted.~Baseline slope: [(FEV1% at baseline / FEV1% 12 months before treatment) - 1] * 100 After treatment slope: [(FEV1% 12 months after treatment / FEV1% at baseline) - 1] * 100" (NCT03623698)
Timeframe: Change from the baseline (before treatment) and 12 months after treatment

Intervention	percentage of predicted (Median)
Before Treatment	-8.03
After Treatment	4.00

FVC% Predicted Rate of Decline

"Rate of decline of Forced Vital Capacity (FVC) percentage of predicted. Rate of decline is a measure of slope of FVC%.~Baseline slope: [(FVC% at baseline / FVC% 12 months before treatment) - 1] * 100 After treatment slope: [(FVC% 12 months after treatment / FVC% at baseline) - 1] * 100" (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	percentage of predicted (Median)
Before Treatment	-7.44
After Treatment	7.00

Nocturnal ODI

Oxygen desaturation index: Number of desaturations per hour of sleep (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	Events per hour of sleep (Mean)
Before Treatment	4.26
After Treatment	3.32

Number of Hospitalsations Due to Respiratory Exacerbations

Number of respiratory exacerbations that required not planned hospitalisation (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	Hospitalisations (Median)
Before Treatment	1
After Treatment	0

Peak Expiratory Flow (PEF)

Peak expiratory flow percentage of predicted (NCT03623698)
Timeframe: Change from baseline peak expiratory flow at 12 months after starting treatment with hypertonic saline

Intervention	percentage of predicted (Median)
Before Treatment	43.5
After Treatment	47

Score on the Ease of Airway Clearance From Parents or Legal Guardians

Measures ease of airway clearance through a 1-5 likert scale: 1) Very easy, 2) Easy, 3) Neither easy nor difficult, 4) Not easy, 5) Not at all easy. (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	score on a scale (Mean)
Before Treatment	4.21
After Treatment	2.13

Score on the Ease of Airway Clearance Pictorial Analogue Scale From Children and Young Adults as Participants

"Pictorial visual scale Facial Rating of perceived exertion Scale. Measures ease of airway clearance. Values range starting in 0 (Extremely easy) to 10 (Extremely hard), including 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Numbers are also associated with facial expressions." (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	score on a scale (Mean)
Before Treatment	6.45
After Treatment	2

TcPCO2

Nocturnal Transcutaneous Carbon Dioxide in kPa (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	Kilopascal (kPa) (Mean)
Before Treatment	5.77
After Treatment	6.00

Change in Antibiotic Courses

Treatments due to respiratory exacerbations (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	Courses of antibiotics (Median)
	Total courses of antibiotics	Courses of Oral antibiotics	Courses of intravenous antibiotics
After Treatment	1	1.00	0.00
Before Treatment	4	2.50	1.00

Parent's or Legal Guardian's Perception of Treatment

"Hypertonic saline treatment questionnaire for legal guardian. Measures the perception of overall usefulness of nebulised hypertonic saline through a likert scale: Very useful, useful, neither useful or not useful, not useful, not at all useful." (NCT03623698)
Timeframe: At 12 months after starting treatment with hypertonic saline

Intervention	Participants (Count of Participants)
	Very useful	useful	neither useful or not useful	not useful	not at all useful
Parent's or Legal Guardians	15	9	0	0	0

Participant's Perception of Treatment

"Questionnaire: Hypertonic saline treatment questionnaire. Perception of overall usefulness of nebulised hypertonic saline: Useful, Not useful, I don't know." (NCT03623698)
Timeframe: At 12 months after starting treatment with hypertonic saline

Intervention	Participants (Count of Participants)
	Useful	Not useful	I don't know
Children and Young People With Neuromuscular Disease	11	0	0

Reviews

4 reviews available for guaifenesin and Neuromuscular Diseases

Article	Year
Airway clearance in children with neuromuscular weakness. Current opinion in pediatrics, 2006, Volume: 18, Issue:3 Topics: Airway Obstruction; Child; Child, Preschool; Cough; Humans; Infant; Mucus; Muscle Weakness; Neuromus	2006
Respiratory issues in the management of children with neuromuscular disease. Respiratory care, 2006, Volume: 51, Issue:8 Topics: Child; Cough; Drainage; Humans; Infant; Lung Diseases, Obstructive; Mucus; Neuromuscular Diseases; P	2006
Management of airway clearance in neuromuscular disease. Respiratory care, 2006, Volume: 51, Issue:8 Topics: Combined Modality Therapy; Cough; Drainage; Humans; Mucus; Neuromuscular Diseases	2006
Management of airway clearance in neuromuscular disease. Respiratory care, 2006, Volume: 51, Issue:8 Topics: Combined Modality Therapy; Cough; Drainage; Humans; Mucus; Neuromuscular Diseases	2006
Management of airway clearance in neuromuscular disease. Respiratory care, 2006, Volume: 51, Issue:8 Topics: Combined Modality Therapy; Cough; Drainage; Humans; Mucus; Neuromuscular Diseases	2006
Management of airway clearance in neuromuscular disease. Respiratory care, 2006, Volume: 51, Issue:8 Topics: Combined Modality Therapy; Cough; Drainage; Humans; Mucus; Neuromuscular Diseases	2006
Airway clearance applications in the elderly and in patients with neurologic or neuromuscular compromise. Respiratory care, 2007, Volume: 52, Issue:10 Topics: Aged; Aging; Airway Obstruction; Humans; Lung; Mucus; Nervous System Diseases; Neuromuscular Disease	2007

Other Studies

2 other studies available for guaifenesin and Neuromuscular Diseases

Article	Year
[Therapy of spastic syndromes]. Bibliotheca psychiatrica et neurologica, 1969, Volume: 139 Topics: Carisoprodol; Chlordiazepoxide; Chlormezanone; Chlorzoxazone; Curare; Diazepam; Guaifenesin; Humans;	1969
[Therapeutic strategies to increase the effectiveness of cough]. Revista medica de Chile, 2014, Volume: 142, Issue:2 Topics: Cough; Forced Expiratory Volume; Humans; Insufflation; Mucus; Neuromuscular Diseases; Positive-Press	2014